Ireland-based Elan Corp and US firm Biogen Idec say that the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee of the US Food and Drug Administration will jointly review their Tysabri (natalizumab) for the treatment of Crohn's disease on July 31.
On December 15, 2006, the companies announced that they submitted to the FDA a supplemental Biologics License Application for the drug as a treatment for moderately-to-severely-active Crohn's disease. This sBLA includes the results of three randomized, double-blind, placebo-controlled, multicenter trials of Tysabri assessing the safety and efficacy as both an induction and maintenance therapy - ENCORE (Efficacy of Natalizumab in Crohn's Disease Response and Remission), ENACT-1 (Efficacy of Natalizumab as Active Crohn's Therapy) and ENACT-2 (Evaluation of Natalizumab As Continuous Therapy).
The sBLA includes data from more than 1,500 Crohn's patients treated with the drug, as well as proposed labeling and a risk management plan. Tysabri is a humanized monclonal antibody believed to block entry of inflammatory immune cells into the wall of the intestine, thus limiting inflammatory damage in Crohn's disease. It is the first potential treatment for Crohn's disease with this proposed mechanism of action, the firms contend.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze